TG4001
HPV-Positive Cancers
Phase IIActive (Status Unclear Post-Refocus)
Key Facts
Indication
HPV-Positive Cancers
Phase
Phase II
Status
Active (Status Unclear Post-Refocus)
Company
About transgene-sa
Transgene SA is a clinical-stage biotech focused on developing Individualized Neoantigen Therapeutic Vaccines (INTV) for early-stage solid tumors. The company's core asset is the myvac® platform, a viral vector system designed to elicit potent, tumor-specific T-cell responses. Under CEO Alessandro Riva, Transgene has undergone a strategic refocusing, prioritizing its lead program TG4050 in head and neck cancer, supported by a cash runway into early 2028. Recent Phase I data, presented as a preprint, suggests potential in preventing cancer relapse.
View full company profile